Phase I/II multicenter trial of paclitaxel, ramucirumab and nivolumab for metastatic gastric cancer patients who progressed on chemotherapy with fluoropyrimidine plus platinum

Trial Profile

Phase I/II multicenter trial of paclitaxel, ramucirumab and nivolumab for metastatic gastric cancer patients who progressed on chemotherapy with fluoropyrimidine plus platinum

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, thirty-five patients have been erolled since Feb 2017.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Status changed from not yet recruiting to recruiting, according to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top